• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

ATAZANAVIR Drug Record

  • Summary
  • Interactions
  • Claims
  • ATAZANAVIR chembl:CHEMBL1163 Approved

    Alternate Names:

    BMS-232632
    CGP-73547
    ATAZANAVIR
    REYATAZ
    LATAZANAVIR
    ZRIVADA
    ATV
    ATAZANAVIRUM
    ATZ
    chemidplus:198904-31-3
    chembl:CHEMBL1163
    rxcui:343047
    pubchem.compound:148192
    drugbank:01072

    Drug Info:

    (0 More Sources)

    Publications:

    Lankisch TO et al., 2006, Gilbert's disease and atazanavir: from phenotype to UDP-glucuronosyltransferase haplotype., Hepatology
    Tamraz B et al., 2020, Association of Pharmacogenetic Markers With Atazanavir Exposure in HIV-Infected Women., Clin Pharmacol Ther
    da Rocha IM et al., 2015, Polymorphisms associated with renal adverse effects of antiretroviral therapy in a Southern Brazilian HIV cohort., Pharmacogenet Genomics
    Rodríguez Nóvoa et al., 2006, Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1., Clin. Infect. Dis.
    Castillo-Mancilla JR et al., 2016, Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342)., J Antimicrob Chemother
    Bonora S et al., 2015, Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study)., J Antimicrob Chemother
    Schipani A et al., 2010, Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance., Antimicrob Agents Chemother
    Siccardi M et al., 2008, Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C-->T) with reduced concentrations of unboosted atazanavir., Clin Infect Dis
    Kile DA et al., 2012, A population pharmacokinetic-pharmacogenetic analysis of atazanavir., AIDS Res Hum Retroviruses
  • ATAZANAVIR   SORCS2

    Interaction Score: 13.74

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31562781


    Sources:
    PharmGKB

  • ATAZANAVIR   UGT1A7

    Interaction Score: 1.53

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17058217


    Sources:
    PharmGKB

  • ATAZANAVIR   UGT1A3

    Interaction Score: 0.98

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17058217


    Sources:
    PharmGKB

  • ATAZANAVIR   NR1I2

    Interaction Score: 0.31

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26892777 26174719 20921307 18831695


    Sources:
    PharmGKB

  • ATAZANAVIR   ABCC2

    Interaction Score: 0.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26287941


    Sources:
    PharmGKB

  • ATAZANAVIR   SLCO1B1

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • ATAZANAVIR   ABCB1

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16355344


    Sources:
    NCI

  • ATAZANAVIR   CYP3A4

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22394315


    Sources:
    PharmGKB

  • ATAZANAVIR   CYP2C19

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • NCI: ATAZANAVIR

    • Version: 14-September-2017

    Alternate Names:
    C28835 NCI drug code

    Drug Info:

    Publications:
    Rodríguez Nóvoa et al., 2006, Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1., Clin. Infect. Dis.

  • PharmGKB: atazanavir

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Castillo-Mancilla JR et al., 2016, Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342)., J Antimicrob Chemother
    Bonora S et al., 2015, Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study)., J Antimicrob Chemother
    Siccardi M et al., 2008, Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C-->T) with reduced concentrations of unboosted atazanavir., Clin Infect Dis

  • TTD: Atazanavir

    • Version: 2020.06.01

    Alternate Names:
    D07IQS TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1163

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21